Pfizer’s Humira Biosimilar Displays Positive Top Line Results
PF-06410293 met primary endpoints during clinical trials and demonstrated similar efficacy to its reference product.
Results from a REFLECTIONS B538-02 trial with Pfizer’s investigational Humira (adalimumab) biosimilar, PF-06410293, showed that the drug met its primary endpoint, and demonstrated similar efficacy to its reference product. PF-06410293 is being evaluated in combination with methotrexate as a treatment for moderate to severe rheumatoid arthritis, the company said in a Jan. 5, 2017 announcement.
PF-06410293 is Pfizer’s second proposed inflammation biosimilar. The company’s pipeline consists of eight biosimilar molecules in mid- to late-stage development. Pfizer also said it has several other biosimilar molecules currently in early-stage development. Pfizer will likely face competition in the Humira biosimilar market. FDA approved the first biosimilar to Humira, Amjevita (adalimumab-atto), marketed by Amgen in the United States, in late September 2016.
Source: Pfizer
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
